Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loracarbef Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | SLC15A2 | Q16348 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loracarbef Anhydrous SCHEMBL1819705 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL34153 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL9017047 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL12306378 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL235140 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL10692457 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL13457172 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL17530968 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL17530291 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| Loracarbef Anhydrous SCHEMBL1229813 | 0.99 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| US-20060205938-A1 | Monohydrate solvates of loracarbef | RANBAXY LABORATORIES LIMITED (IN) | 2006-09-14 | — | — | US | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| US-20030176327-A1 | Antibiotics for treating biohazardous bacterial agents | CASSELL GAIL HOUSTON (US) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | KDM4E 1244/4885ALDH1A1 2455/4885HSD17B10 581/4885 |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | KDM4E 2934/4885ALDH1A1 1039/4885HSD17B10 2020/4885 |
| US-20060205938-A1 | Monohydrate solvates of loracarbef | SLC10A1, DCXR, KLK13 | KDM4E 324/4885ALDH1A1 1056/4885HSD17B10 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.